Prot#253MS201: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple S

Project: Research project

Project Details

StatusFinished
Effective start/end date1/22/21 → 1/21/22

Funding

  • DrugDev Inc. (Prot#253MS201 // Prot#253MS201)
  • Biogen MA Inc. (Prot#253MS201 // Prot#253MS201)